Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by PWIB123on Mar 25, 2022 5:38pm
102 Views
Post# 34547107

RE:RE:RE:Common business sense

RE:RE:RE:Common business senseLet's just hope we have less investors who are scientists and more who are looking for any signal of value creation that incentivizes them to buy more shares before everything is completely understood.  Phew!  You all are tough. 

palinc2000 wrote: Maybe we should manage our expectations with respect to the certainty of initiating  Phase 1 b ......unless they can convince a big pharma to get involved



Wino115 wrote: I agree with you, but would just say that from what we have read in the scientific literature and from what Beleiveu and Marsolais have said, they are at the earliest stage of investigating the usefullness of sort1 as a targeting approach. They literally are the vanguard here.  We know there is the Sortina Bio group doing it, but approaching it from the view of sort1 being related to stem cell proliferation too; thus, target sort1 to silence cancer stem cell proliferation (what THTX has identified as a possible secondary effect a la VM and metastices and stem cell death in their latest AACR abstract). I do believe them when they say they are first as none of us have found anything else. It's also why we and the market aren't ascribing much value to it yet. Many of the internal doubts we all have revolve around that idea --why aren't others investigating this?  But you could have asked that same question in 2017 around Trop2, or Nectin-4 (PadCev), or HER2, CD19, etc.. As we know, there are only around 12 ADCs on the market at this point, so the entire field is still in it's infancy if you consider there are likely thousands of potential targets out there.

There's always a first identifier of a target, and then the copy-cats (or partners) come in. Until they prove up the target usefullness, we shouldn't expect it. But like you say, looking at the history around the ADC targets that have exploded in popularity, it should happen if it's effective. Unfortunately we don't know yet whether sort1 is definitievely a useful target or not in humans.



palinc2000 wrote: Large pharmas and large bios are like hound dogs ....If they spot or scent a breakthru in oncology they  come fast and furious and will want to get a piece of the action ,,,,,,We can debate all we want on proof of concept but the real validation imo will be  if and when a third party shows up .....There is no way that THTX would close the door to some kind of collaboration even in the early part of Phase 1 b .....Big pharmas have very deep  pockets and are not risk adverse but they need to see some glimse of hope .....





















 

 




<< Previous
Bullboard Posts
Next >>